<DOC>
	<DOC>NCT02427035</DOC>
	<brief_summary>This is a phase 1 multicenter, randomized, double-blind, placebo-controlled, ascending dose study to investigate the pharmacokinetics (PK), safety, and tolerability of CSL112 in adult subjects with moderate renal impairment and in healthy adult subjects with normal renal function.</brief_summary>
	<brief_title>A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Men or women aged 18 to 85 years (inclusive) of age, with body weight 50 kg or more. Subjects with renal impairment (RI) must have stable chronic moderate RI (estimated glomerular filtration rate [eGFR] ≥ 30 and &lt; 60 mL/min/1.73 m2) Healthy subjects must have normal renal function (eGFR ≥ 90 mL/min/1.73 m2) Evidence of a clinically significant medical condition, disorder or disease Evidence of hepatobiliary disease Any clinically relevant abnormal laboratory test result Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its components Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study, including: history of cancer, low platelet count, bleeding disorder or coagulopathy, significantly altered electrocardiogram waveform, unstable glycemia control in subjects with diabetes, acute renal failure, recent donation or loss of blood Evidence or history of alcohol or substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>